Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Highlights in lymphoma at ASH 2020

Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, highlights the key updates in lymphoma from the American Society of Hematology (ASH) 2020 Annual Meeting and Exposition. Dr. Jagadeesh’s perspectives are that CAR T-cell therapy is evolving to be first-line therapy for patients with mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), as opposed to relapse therapy. Data on lisocabtagene maraleucel (liso-cel) will be presented which have had encouraging response rates in large B-cell lymphoma. Additionally, exciting results on bispecific antibodies will be presented, including anti-CD3/CD20 antibodies as treatment for patients that have relapsed after CAR T-cell therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research funding: MEI Pharma, Debiopharm Group, Regeneron
Membership on an entity’s Board of Directors or advisory committees: Verastem, Seattle Genetics